Recombinant Human Anti-CD28 x Human Anti-CD30 Bispecific Antibody (scFv-Fc) (BSCFV-H231)

Recombinant Anti-CD28 x Anti-CD30 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD28 specificity or anti-CD30 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CD30

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CD30

Gene ID

943

UniProt ID

A5D8T4

Alternative Names

TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD28 x Human Anti-CD30 Bispecific Antibody (scFv-Fc) (BSCFV-H231). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD28 x Human Anti-CD30 Bispecific Antibody (scFv-Fc) (CAT#: BSCFV-H231)

Specifications

Targets

Customer Reviews and Q&As